Lee Gina, Gardner Brian K, Elashoff David A, Purcell Colleen M, Sandha Harpavan S, Mao Jenny T, Krysan Kostyantyn, Lee Jay M, Dubinett Steven M
Am J Transl Res. 2011 May 15;3(3):226-33. Epub 2011 Apr 2.
Despite advances in treatments, lung cancer has been the leading cause of cancer-related deaths in the United States for the past several decades. Recent findings from the National Lung Screening Trial reveal that low-dose helical computed tomography (CT) scan screening of high-risk individuals reduces lung cancer mortality. This suggests that early detection is of key importance to improving patient outcome. However, of those screened with CT scans, 25% had positive scans that require further follow-up studies which often involve more radiation exposure and invasive tests to reduce false positive results. The purpose of this study was to identify candidate plasma biomarkers to aid in diagnosis of lung cancer in at-risk individuals. We found increased expression of the CXC chemokine connective tissue-activating peptide (CTAP)-III from plasma specimens of lung cancer patients compared to at-risk control subjects. Identification of the peptide was confirmed by the addition of an anti-NAP-2 antibody that recognizes CTAP-III and NAP-2. We also quantified and verified the increased levels of plasma CTAP-III with ELISA in patients with lung cancer (mean ± SD, 1859 ± 1219 ng/mL) compared to controls (698 ± 434 ng/mL; P<0.001). Our findings demonstrate elevated plasma levels of CTAP-III occur in lung cancer patients. Further studies are required to determine if this chemokine could be utilized in a blood-based biomarker panel for the diagnosis of lung cancer.
尽管治疗方法有所进步，但在过去几十年里，肺癌一直是美国癌症相关死亡的主要原因。国家肺癌筛查试验的最新研究结果显示，对高危个体进行低剂量螺旋计算机断层扫描（CT）筛查可降低肺癌死亡率。这表明早期检测对于改善患者预后至关重要。然而，在接受CT扫描的人群中，25%的扫描结果呈阳性，需要进一步的后续研究，这些研究通常涉及更多的辐射暴露和侵入性检查，以减少假阳性结果。本研究的目的是确定候选血浆生物标志物，以帮助诊断高危个体的肺癌。我们发现，与高危对照受试者相比，肺癌患者血浆样本中CXC趋化因子结缔组织激活肽（CTAP）-III的表达增加。通过添加识别CTAP-III和NAP-2的抗NAP-2抗体，证实了该肽的鉴定。我们还通过酶联免疫吸附测定（ELISA）定量并验证了肺癌患者血浆CTAP-III水平（平均值±标准差，1859±1219 ng/mL）高于对照组（698±434 ng/mL；P<0.001）。我们的研究结果表明，肺癌患者血浆中CTAP-III水平升高。需要进一步研究以确定这种趋化因子是否可用于基于血液的生物标志物组合来诊断肺癌。
